Allakos Inc. (ALLK)
NASDAQ: ALLK · Real-Time Price · USD
0.286
-0.005 (-1.72%)
At close: Feb 21, 2025, 4:00 PM
0.282
-0.004 (-1.44%)
After-hours: Feb 21, 2025, 7:58 PM EST
Company Description
Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States.
The company’s lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications.
The company was incorporated in 2012 and is headquartered in San Carlos, California.
Allakos Inc.
| Country | United States |
| Founded | 2012 |
| IPO Date | Jul 19, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 131 |
| CEO | Robert Alexander |
Contact Details
Address: 825 Industrial Road, Suite 500 San Carlos, California 94070 United States | |
| Phone | 650 597 5002 |
| Website | allakos.com |
Stock Details
| Ticker Symbol | ALLK |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001564824 |
| CUSIP Number | 01671P100 |
| ISIN Number | US01671P1003 |
| Employer ID | 45-4798831 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert Alexander Ph.D. | Chief Executive Officer and Director |
| Dr. Adam L. Tomasi Ph.D. | President |
| Baird Radford III | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 3, 2025 | SCHEDULE 13D | Filing |
| Jan 27, 2025 | 8-K | Current Report |
| Jan 27, 2025 | 8-K | Current Report |
| Jan 13, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 6, 2024 | 144 | Filing |
| Dec 6, 2024 | 144 | Filing |
| Dec 5, 2024 | 144 | Filing |
| Dec 4, 2024 | 144 | Filing |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |